Abstract: A power supply control apparatus comprises a first power supply supplying power to a controller and a second power supply supplying power to an operation unit and a power controller. The operation unit receives an operation for switching the first power supply on and off. The power controller is operable to turn on the first power supply according to the signal from a timer or the operation by the operation unit, and to turn off the first power supply according to a state of the controller. The controller, upon at least either of the operation by the operation unit or the signal from the timer, performs a setting to the timer of a time at which to turn on the power from the first power supply or a time at which to turn off the power from the first power supply.

Abstract: A maintenance plan assistance system 100 configured to include: holding, in a storage device 101, remaining life information relating to devices covered by a maintenance plan, and a list of maintenance menus; and a computation device 104 identifying a maintenance effect when each maintenance menu is applied to each of the devices based on the maintenance menus and temporal changes in failure probabilities of each of the devices indicated by the remaining life information, identifying a variable range of a condition-based maintenance implementation timing, the variable range being dependent on the maintenance effect, and determining a maintenance menu including the variable range for a predetermined maintenance timing, and outputting, to a predetermined device, information including the maintenance menu identified by the determination and the condition-based maintenance implementation timing changed to the predetermined maintenance timing.

Abstract: The problem of the present invention is to establish how to more accurately estimate the failure probabilities of the components of a machine system that has a small number of failure records.

Abstract: The problem of the present invention is how to identify a failure probability function that defines failure occurrences of a device or a component of the device that is operated while undergoing maintenance in consideration of effects of the maintenance.

Abstract: Provided are a fracture surface analysis apparatus and a fracture surface analysis method which enable a non-expert to conduct a fracture surface analysis just as well as an expert does. This fracture surface analysis apparatus is characterized by including a microscopic region observation unit that is provided with a first means for calculating an accuracy of fracture mode by using a first observation image, of a microscopic region of a to-be-analyzed object, acquired by an imaging means, a second means for calculating an observation condition for improving the accuracy of the fracture mode, and a third means for adjusting conditions for imaging the microscopic region by the imaging means, and that outputs the accuracy of fracture mode and the observation condition for improving the accuracy of fracture mode to a visualization means.

Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.

Abstract: The remaining life of a component of a mechanical system is predicted with high accuracy. A failure probability evaluation system evaluates a failure of a component of each mechanical system for a mechanical system group including a plurality of mechanical systems, and includes a failure history database for accumulating past failure history data about the mechanical system. A time-series operation database stores time-series physical quantity data representing an operating state of the mechanical system. A failure rate function identification unit calculates a failure rate function of a mechanical system by statistical processing based on the failure history data, and a damage model generation/update unit having a function of generating an explanatory variable expression of a failure rate function which minimizes a variation in life is defined by the failure rate function using the time-series physical quantity data.

Abstract: To provide high-accuracy assessment of a remaining life of a composite material structure. A remaining life assessment system 5 for composite material structure includes: a load history assessment part 7 that calculates a history of load on a composite material based on output from a first sensor attached to the composite material; a state quantity assessment part 10 that calculates a state quantity of the composite material based on output from the first sensor or a second sensor; a state quantity change database 13 that holds previously recorded relation between the load history and the state quantity of the composite material; and a comparative assessment part 12 that compares the calculated load history and state quantity with the load history and state quantity stored in the state quantity change database 13.

Abstract: To provide high-accuracy assessment of a remaining life of a composite material structure. A remaining life assessment system 5 for composite material structure includes: a load history assessment part 7 that calculates a history of load on a composite material based on output from a first sensor attached to the composite material; a state quantity assessment part 10 that calculates a state quantity of the composite material based on output from the first sensor or a second sensor; a state quantity change database 13 that holds previously recorded relation between the load history and the state quantity of the composite material; and a comparative assessment part 12 that compares the calculated load history and state quantity with the load history and state quantity stored in the state quantity change database 13.

Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

Abstract: An object of the present invention is to provide a capsule formulation comprising a phosphonooxymethyl derivative of ravuconazole which suppresses delay in dissolution due to storage regardless of an encapsulated amount of the phosphonooxymethyl derivative of ravuconazole. The present invention provides a capsule formulation comprising an encapsulated material comprising {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing, and a capsule shell not comprising gelatin.

Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.

Abstract: An object of the present invention is to provide a capsule formulation comprising a phosphonooxymethyl derivative of ravuconazole which suppresses delay in dissolution due to storage regardless of an encapsulated amount of the phosphonooxymethyl derivative of ravuconazole. The present invention provides a capsule formulation comprising an encapsulated material comprising {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing, and a capsule shell not comprising gelatin.

Abstract: An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition.

Abstract: The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.

Abstract: The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.

Abstract: A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a dissolution rate of the basic drug or the salt thereof in an acidic test solution to a dissolution rate of the basic drug or the salt thereof in a neutral test solution (dissolution rate in the acidic test solution/dissolution rate in the neutral test solution) decreases with dissolution time at the late stage of dissolution, as compared to the early stage of dissolution. According to the present invention, the matrix type sustained-release preparation contains a basic drug or a salt thereof and at least one enteric polymer, in which solubility of the basic drug or the salt thereof in a 0.1 N hydrochloric acid solution and a neutral aqueous solution, pH 6.0 is higher than in a basic aqueous solution, pH 8.0.